Taniya Ahuja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taniya Ahuja has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Amanda L. Bain
QIMR Berghofer Medical Research Institute
13 shared publications - Amy Ives
16Department of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Australia
13 shared publications - Aravind Anandam
Department of In Vivo Pharmacology, Biology, Sai Life Sciences, Hyderabad, India
13 shared publications - Debottam Sinha
QIMR Berghofer Medical Research Institute
13 shared publications - Desmond Yip
Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia
13 shared publications - Gahyathiri Nallan
Gene Regulation and Translational Medicine Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
13 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S1. List of the PI3K/mTOR inhibitors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S1. List of the PI3K/mTOR inhibitors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S3. Inhibition of human PI3K isoenzymes in vitro by paxalisib in fluorescence polarization biochemical assays.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S3. Inhibition of human PI3K isoenzymes in vitro by paxalisib in fluorescence polarization biochemical assays.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Methods to accompany manuscript
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Methods to accompany manuscript
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Results to accompany manuscript
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Results to accompany manuscript
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 3. NanoString nCounter analysis highlighting distinct gene expression profiles in Paxalisib-treated tumors.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 3. NanoString nCounter analysis highlighting distinct gene expression profiles in Paxalisib-treated tumors.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 7. Associations between PIK3R2 gene expression and survival probability amongst TNBC patient cohorts.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 7. Associations between PIK3R2 gene expression and survival probability amongst TNBC patient cohorts.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 2. Dose de-escalation of the PI3K-mTOR inhibitor, paxalisib, overcomes toxicity burden in combination treatments.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 2. Dose de-escalation of the PI3K-mTOR inhibitor, paxalisib, overcomes toxicity burden in combination treatments.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Upplementary Table S2. The 23 antibody CODEX panel.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Upplementary Table S2. The 23 antibody CODEX panel.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 6. EZH2 co-localizes with NF-κB to activate pro-oncogenic gene expression in TNBC.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 6. EZH2 co-localizes with NF-κB to activate pro-oncogenic gene expression in TNBC.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 4. Nuclear p85β expression in Stage III TNBC patients and paxalisib- treated 4T1 TNBC mice.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 4. Nuclear p85β expression in Stage III TNBC patients and paxalisib- treated 4T1 TNBC mice.